Arrivo BioVentures

7 articles about Arrivo BioVentures

• Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator

  4/16/2024

  Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.

• Psychiatry and Neuroscience Expert Dr. Joel Raskin Joins ArrivoBio as Chief Medical Advisor

  1/3/2024

  Arrivo BioVentures proudly announces the appointment of Dr. Joel Raskin as its Chief Medical Advisor.

• ArrivoBio Raises $45M in Series B Financing to Advance Pipeline

  11/29/2023

  Arrivo BioVentures today announced the closing of an oversubscribed Series B preferred financing round, totaling $100M.

• Arrivo BioVentures Closes Enrollment in Large Phase 2 Clinical Trial for Major Depressive Disorder

  5/26/2022

  Arrivo BioVentures announced today that the company has closed enrollment of a phase 2 clinical study with its most advanced program, SP-624, after having enrolled more than 300 patients with major depressive disorder.

• What You Need to Know About Arrivo BioVentures

  1/23/2017

• 

  The Next Generation: Top 20 Life Science Startups to Watch in 2017

  1/9/2017

  BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.

• Serial BioPharma Entrepreneurial Team Launches Arrivo BioVentures with $49 Million

  5/25/2016